0 515

Cited 11 times in

Insufficient bilateral femoral subtrochanteric fractures in a patient receiving imatinib mesylate

DC Field Value Language
dc.contributor.author양규현-
dc.date.accessioned2015-04-23T17:22:08Z-
dc.date.available2015-04-23T17:22:08Z-
dc.date.issued2010-
dc.identifier.issn0914-8779-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/102328-
dc.description.abstractWe present a case of insufficient bilateral femoral subtrochanteric fractures in a patient who was treated with imatinib mesylate, an anticancer drug, for 1 year after a diagnosis of chronic myelogenous leukemia (CML). A 60-year-old woman presented with bilateral thigh pain for 6 months. A plain radiograph revealed bilateral progressive insufficient fractures on the subtrochanteric areas of the femurs. MRI of the femurs revealed incomplete stress fractures and no evidence of bone metastasis on either femur. Bone densitometry showed normal T-scores around the hip joint and spine. The patient had normal serum levels of calcium, vitamin D derivatives, and thyroid hormones. Serum phosphate levels were decreased, and parathyroid hormone levels were increased. Serum osteocalcin and urinary N-telopeptide of collagen cross-links (NTx) were both decreased. A bone biopsy demonstrated normocellular marrow without leukemic cells. A histomorphometric evaluation of her bones revealed reduced bone turnover despite secondary hyperparathyroidism. The serum markers for bone metabolism and histomorphometric evaluations in this patient suggest that the drug may have an effect on bone metabolism. These effects could be seen for both bone formation and resorption: this could result in impaired bone mineralization, a severely suppressed bone turnover rate, insufficient fractures, and bone necrosis, which are sometimes seen with long-term use of bisphosphonates. To our knowledge, this is the first case of an insufficient bilateral femoral shaft fracture that is potentially related to the use of imatinib mesylate in a patient with CML. Careful examination of bone metabolism should be performed in patients with CML because imatinib mesylate treatment is a lifelong process.-
dc.description.statementOfResponsibilityopen-
dc.format.extent713~718-
dc.relation.isPartOfJOURNAL OF BONE AND MINERAL METABOLISM-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAntineoplastic Agents/adverse effects*-
dc.subject.MESHAntineoplastic Agents/therapeutic use-
dc.subject.MESHBenzamides-
dc.subject.MESHBone Remodeling/drug effects-
dc.subject.MESHBone and Bones/diagnostic imaging-
dc.subject.MESHBone and Bones/drug effects-
dc.subject.MESHBone and Bones/metabolism-
dc.subject.MESHBone and Bones/pathology-
dc.subject.MESHFemale-
dc.subject.MESHFemoral Fractures/blood-
dc.subject.MESHFemoral Fractures/diagnostic imaging-
dc.subject.MESHFemoral Fractures/etiology*-
dc.subject.MESHFemoral Fractures/surgery-
dc.subject.MESHHumans-
dc.subject.MESHHyperparathyroidism, Secondary/chemically induced*-
dc.subject.MESHHyperparathyroidism, Secondary/physiopathology-
dc.subject.MESHHypophosphatemia/chemically induced*-
dc.subject.MESHHypophosphatemia/physiopathology-
dc.subject.MESHImatinib Mesylate-
dc.subject.MESHLeukemia, Myeloid, Chronic-Phase/drug therapy-
dc.subject.MESHMiddle Aged-
dc.subject.MESHPiperazines/adverse effects*-
dc.subject.MESHPiperazines/therapeutic use-
dc.subject.MESHPyrimidines/adverse effects*-
dc.subject.MESHPyrimidines/therapeutic use-
dc.subject.MESHRadiography-
dc.titleInsufficient bilateral femoral subtrochanteric fractures in a patient receiving imatinib mesylate-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Orthopedic Surgery (정형외과학)-
dc.contributor.googleauthorKyu-Hyun Yang-
dc.contributor.googleauthorSi-Young Park-
dc.contributor.googleauthorSang-Won Park-
dc.contributor.googleauthorSoon-Hyuck Lee-
dc.contributor.googleauthorSeung-Beom Han-
dc.contributor.googleauthorWoong-Kyo Jung-
dc.contributor.googleauthorSuk-Jin Kim-
dc.identifier.doi10.1007/s00774-010-0203-2-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA02282-
dc.relation.journalcodeJ01277-
dc.identifier.eissn1435-5604-
dc.identifier.pmid20607326-
dc.identifier.urlhttp://link.springer.com/article/10.1007%2Fs00774-010-0203-2-
dc.subject.keywordInsufficient fracture-
dc.subject.keywordFemur-
dc.subject.keywordImanitib mesylate-
dc.subject.keywordBone turnover-
dc.contributor.alternativeNameYang, Kyu Hyun-
dc.contributor.affiliatedAuthorYang, Kyu Hyun-
dc.citation.volume28-
dc.citation.number6-
dc.citation.startPage713-
dc.citation.endPage718-
dc.identifier.bibliographicCitationJOURNAL OF BONE AND MINERAL METABOLISM, Vol.28(6) : 713-718, 2010-
dc.identifier.rimsid40859-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Orthopedic Surgery (정형외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.